Last reviewed · How we verify
NCT05678517
Seven-year Outcomes Following Intensive Anti-VEGF Therapy in Wet AMD
trial testing Anti-VEGF in Age-Related Macular Degeneration in 47 participants. Completed in 6 December 2022.
31 December 2017
Quick facts
| Lead sponsor | Semmelweis University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 47 |
| Start date | 1 January 2010 |
| Primary completion | 31 December 2017 |
| Estimated completion | 6 December 2022 |
| Sites | 2 locations across Hungary |
Drugs / interventions tested
- Anti-VEGF (anti-vegf) — full drug profile →
Conditions studied
- Age-Related Macular Degeneration — all drugs for Age-Related Macular Degeneration →
Sponsor
Semmelweis University
Who can join
50 and older, any sex, with Age-Related Macular Degeneration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative AMD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration.
Lukacs R, Schneider M, Nagy ZZ, Sandor GL, et al · · 2023 · cited 4× · PMID 36932356 · DOI 10.1186/s12886-023-02843-2
Verify or expand the search:
- PubMed search for NCT05678517
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Anti-VEGF
Trials testing the same drug.
- NCT07062055 — BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases · Phase 2 · recruiting
- NCT06537908 — Anti-PD-1/PD-L1 Antibodies Plus Anti-VEGF Antibody Treatment in Patients With Advanced-Stage HCC · recruiting
- NCT04626128 — Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD · Phase 1, PHASE2 · completed
- NCT04171141 — Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestin · Phase 1 · terminated
- NCT04962438 — Effects of Anti-VEGF Targeted Drugs on Patients' Blood Pressure and Endothelial Function · unknown
Other recruiting trials for Age-Related Macular Degeneration
Currently open trials in the same condition.
- NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
- NCT06619405 — AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance · NA · recruiting
- NCT06970665 — A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Ma · Phase 4 · recruiting
- NCT06319872 — The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration · Phase 1 · recruiting
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
Other Semmelweis University trials
Trials by the same sponsor.
- NCT07519382 — Comparing the Clinical Success of Two Different CAD/CAM Full Cuspal Coverage Onlays · NA · enrolling by invitation
- NCT07474662 — Comparing the Effectiveness of Online vs. Face-to-face Physiotherapy for Treating Temporomandibular Disorders · NA · recruiting
- NCT07392853 — Investigation of the Effectiveness of Prophylactic NPWT (ciNPWT) in High-risk Diabetic Patients With Acute Laparotomy Wo · NA · not yet recruiting
- NCT07238296 — Prophylactic Sphincterotomy in Acute Biliary Pancreatitis Patients Unfit for Surgery · NA · not yet recruiting
- NCT07104370 — Freeze-dried Bone Allograft vs Autologous Bone Blocks in the Lateral Augmentation of the Jaws · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05678517 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Semmelweis University
- Last refreshed: 10 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05678517.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing